Beigene

This study tested a new drug called BGB-24714 in 157 people with advanced solid tumors that had spread or couldn't be removed. The goal was to find safe doses and see if the drug shrinks tumors when used alone or with chemotherapy or radiation. The trial was stopped early, but re…

This study tested a drug called tislelizumab against standard chemotherapy for people with classical Hodgkin lymphoma that returned or didn't respond to prior treatments. Only 3 people took part before the study was stopped early. The goal was to see if tislelizumab could delay c…

This early-phase study tested a new drug called BGB-30813, alone or with another drug (tislelizumab), in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drugs could shri…

This study tested a new combination of two drugs (ociperlimab and tislelizumab) against the standard drug pembrolizumab for people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. The trial was stopped early, but researchers measured how long patients…

This early-stage study tested a new drug called BGB-A3055, alone or with another drug (tislelizumab), in people with advanced or metastatic solid tumors. The goal was to check safety, how the body handles the drug, and any early signs of tumor shrinkage. The study was stopped ear…

This early-stage study tested a new drug, BGB-B3227, alone or with another drug (tislelizumab) in 35 people with advanced solid tumors. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.